Dr Max Fehlmann has been appointed president and CEO of the Canadian Cancer Society, effective January 16, replacing Andy Chabot after an eight-year term. Fehlmann stepped down as the founding president and CEO of the NEOMED Institute and NEOMED-LABS, its affiliate contract research organization at the end of 2016. Prior to founding NEOMED in 2012, he founded the Consortium Québécois pour la Découverte du Médicament (CQDM) in 2008, a public-private non-profit organization financing precompetitive research in drug discovery. Fehlmann received his PhD in molecular biology from Laval Univ and holds a DSc from the Univ of Nice and an MBA from HEC-CPA in Sophia-Antipolis in Nice. He has more than 35 years of experience in management, financing and business development.